- Home
- CPS vs FBRX Comparison
CPS vs FBRX Comparison
Compare CPS & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPS | FBRX |
|---|---|---|
| Founded | 1960 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 544.9M | 487.2M |
| IPO Year | 2005 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CPS | FBRX |
|---|---|---|
| Price | $30.19 | $17.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $51.88 | ★ $67.00 |
| AVG Volume (30 Days) | 143.9K | ★ 213.8K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.87 | 61.30 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | $4.42 | N/A |
| Revenue Next Year | $6.36 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.38 | $9.12 |
| 52 Week High | $47.98 | $35.80 |
Technical Indicators
Market Signals| Indicator | CPS | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.10 | 28.35 |
| Support Level | $30.64 | $10.50 |
| Resistance Level | $32.05 | $22.84 |
| Average True Range (ATR) | 1.39 | 1.90 |
| MACD | 0.35 | -0.34 |
| Stochastic Oscillator | 96.74 | 4.98 |
Price Performance
Historical ComparisonAbout CPS Cooper-Standard Holdings Inc.
Cooper-Standard Holdings Inc is engaged in the manufacture of sealing and fluid handling systems (consisting of fuel and brake delivery systems and fluid transfer systems). Its products are designed for passenger vehicles and light trucks that are manufactured by automotive original equipment manufacturers (OEMs) and replacement markets. It has two reportable segments: Sealing Systems and Fluid Handling Systems. The group's geographic regions are North America, Europe, Asia Pacific, and South America.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.